Anandabazar আরটিআইয়ে নালিশ জমতে জমতে পাহাড় নিজস্ব সংবাদদাতা
কলকাতা ০৫ জুলাই ২০২১ ০৭:০৯
প্রতীকী ছবি।
রাজ্যে সরকারি প্রকল্প অসংখ্য। কিন্তু কোনও দফতর বা প্রকল্প সম্পর্কে তথ্য জানতে হলে নাগরিকদের গড়ে অপেক্ষা করতে হবে সাড়ে সাতটি বছর! আরটিআই বা তথ্যের অধিকার আইনের আওতায় পশ্চিমবঙ্গ তথ্য কমিশনে দায়ের হওয়া অভিযোগের নিষ্পত্তি সংক্রান্ত তথ্য ও পর
Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
-derived asparaginase treatments
Company to host investor webcast in July; details to follow
DUBLIN, July 1, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in pediatric and adult patients one month and older who have developed hypersensitivity to
Share this article
Share this article
DUBLIN, June 30, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze
™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in pediatric and adult patients one month and older who have developed hypersensitivity to
E. coli-derived asparaginase.
1
Rylaze is the only recombinant erwinia asparaginase manufactured product that maintains a clinically meaningful level of asparaginase activity throughout the entire duration of treatment, and it was developed by Jazz to address the needs of patients and healthcare providers with an innovative, high-quality erwinia-derived asparaginase with reliable supply.